Dr. Phil Febbo was appointed as Illumina’s chief medical officer in March 2018 and is responsible for developing and executing the company’s medical strategy to drive genomic testing into health care practice. Dr. Febbo has a successful track record of translational research, clinical excellence, and embedding molecular insights into clinical care. Before Illumina, Dr. Febbo served as CMO of Genomic Health for five years. Prior to that, Dr. Febbo was a professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer.